Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | CETP | P11597 | 3/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | ALPG | P10696 | 1/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | LAP3 | P28838 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28244553 | 0.98 | TSHR (0.68) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL12732389 | 0.83 | TSHR (0.48) | TSHRCETPKDM4E | |
| SCHEMBL22402591 | 0.83 | TSHR (0.70) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL3367142 | 0.83 | TSHR (0.63) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL206610 | 0.83 | TSHR (0.76) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL51316 | 0.83 | TSHR (1.00) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL27908642 | 0.83 | TSHR (1.00) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL6685550 | 0.83 | TSHR (0.76) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL389180 | 0.83 | TSHR (0.63) | TSHRCETPFOLH1SRCPDPK1 | |
| SCHEMBL6135587 | 0.82 | TSHR (0.68) | TSHRCETPFOLH1SRCPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-108619161-A | Acyclic nucleoside phosphonate diester | 加利福尼亚大学董事会 | 2018-10-09 | — | — | CN | disclosed |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9698186-B2 | Near-infrared-absorbing composition, near-infrared cut-off filter using same, camera module, and manufacturing method therefor | FUJIFILM CORPORATION (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9698186-B2 | Near-infrared-absorbing composition, near-infrared cut-off filter using same, camera module, and manufacturing method therefor | FUJIFILM CORPORATION (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9663543-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170088576-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9579332-B2 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1389624-A1 | Phosphorous-containing cysteine and serine protease inhibitors | CEPHALON, INC. (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6043341-A | PHOSPHONYLATING AGENTS FOR REGIOSELECTIVE AND REPRODUCIBLE CONVERSION OF PEPTIDES TO PHOSPHONIC ACID PRODRUGS | ELI LILLY & CO. (US) | 2000-03-28 | — | — | US | disclosed |
| CN-1230889-A | NAALADase compositions and methods for treating glutamate abnormalities and for producing neuronal activity in animals | GUILFORD PHARM INC (US) | 1999-10-06 | — | — | CN | disclosed |
| EP-0906915-A1 | Preparation of cyclic peptide antifungal agents | ELI LILLY AND COMPANY (US) | 1999-04-07 | — | — | EP | disclosed |
| WO-1999006062-A1 | CYCLIC PEPTIDE ANTIFUNGAL AGENTS | ELI LILLY AND COMPANY (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0871454-A4 | — | — | 1998-11-25 | — | — | EP | disclosed |
| EP-0871454-A1 | PHOSPHOROUS-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5639732-A | FOR TREATING NERVOUS SYSTEM DISORDERS OR AS ANTIINFLAMMATORY AGENT | CEPHALON, INC. (US) | 1997-06-17 | — | — | US | disclosed |
| WO-1997003679-A1 | PHOSPHOROUS-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088576-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, ITPA | TSHR 4801/4885CETP 1795/4885FOLH1 2584/4885 |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | TSHR 2776/4885CETP 3827/4885FOLH1 414/4885 |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | TSHR 2182/4885CETP 2424/4885FOLH1 1935/4885 |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | PIK3CA, TYMP, ITPA | TSHR 4872/4885CETP 1688/4885FOLH1 1748/4885 |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | TSHR 4872/4885CETP 1688/4885FOLH1 1748/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | TSHR 4782/4885CETP 2347/4885FOLH1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.